Pluristyx, Inc.

In collaboration with Defined Bioscience, we've published a new application note for our #PluriKit. This kit, available with our induced pluripotent stem cells, provides you with the necessary reagents to culture and generate a small working bank of #iPSCs, minimizing variability to achieve robust expansion, effective cryopreservation, and reliable post-thaw recovery. Why source from multiple vendors when you can buy what you need as a pre-packaged, validated set of reagents and protocols for consistent growth of iPSCs?

Discover more about our CEO, Benjamin Fryer, his inspiration behind founding Pluristyx, and our exciting plans for 2025 in a recent interview conducted by Bullpen at #JPM2025. Our commitment to revolutionizing regenerative medicine aligns perfectly with the spirit of this event. We're proud to support the development of groundbreaking cellular therapies that have the potential to transform patient care.? #CellTherapy #Innovation #VentureCapital

Check it out! Pluristyx has joined forces with Teknova, a leading reagents manufacturer, to expand access to our proprietary cryopreservation system, PluriFreeze.

?? PluriPost Alert - Exploring Genetic Stability in iPSCs ?? Our team recently delved into the genetic stability of cultured induced pluripotent stem cells (iPSCs) in a new publication. We're excited to expand on their insights and highlight how Pluristyx's approaches and technologies can help. ?? Genetic Abnormalities in iPSCs: Continuous propagation of cells inevitably leads to genetic abnormalities, raising concerns for PSC-derived cell therapies. These changes occur stochastically, but selective pressures in cell culture can favor growth-advantageous alterations, potentially leading to malignant outgrowths in patients. ??? Mitigating Risks: At Pluristyx, we prioritize understanding, minimizing, and mitigating these genetic occurrences. Here are some of our strategies: ? 1. Careful Donor Selection: We select donors based on age, gender, blood type, and collection site to ensure genetic integrity. For example, we prefer skin fibroblasts from less sun-exposed areas and mesenchymal stem cells for their UV protection. 2. Robust Screening: Using NGS-based probing, we screen donor cells for genetic abnormalities to establish confidence in the starting material. 3. Minimizing Cell Stress: Our cell reprogramming and banking protocols minimize cell stress, ensuring a healthy and stable iPSC population. We use small molecules like ROCK inhibitors and nucleoside supplementation to reduce selective pressure and DNA alterations. 4. Genetic Integrity Checkpoints: We implement stage-appropriate checkpoints during cell expansion and after banking to detect genetic abnormalities early. This includes CNV analysis and gene amplification probing. 5. Molecular Safety Switches: Technologies like the FailSafe? mechanism provide an inducible cell suicide switch, activated by Ganciclovir, to remove target cells if DNA alterations are detected. At Pluristyx, Inc., we are committed to delivering safe and effective starting material for cell therapies. Let's continue to innovate and ensure the highest standards for patient safety. Read more: https://lnkd.in/gBmUErjF #CellTherapy #iPSCs #GeneticStability #Pluristyx #Biotech #StemCells?

Congratulations to BlueRock Therapeutics and Bayer on receiving Fast Track designation from the FDA for OpCT-001, an investigational iPSC-derived cell therapy for the treatment of primary photoreceptor diseases! ?? At Pluristyx, we believe that iPSCs have tremendous potential as the foundation for next-generation cell therapies and regenerative medicines. This milestone exemplifies the remarkable progress being made in using iPSC-based therapies to treat serious medical conditions and enhance the lives of patients. As we continue to advance off-the-shelf, scalable iPSC solutions, we celebrate the teams at BlueRock and Bayer for their dedication to developing innovative, life-changing treatments, bringing vision and hope back to patients facing these devastating disorders. Read more: https://lnkd.in/eS2NcTXj #CellTherapy #RegenerativeMedicine #iPSCs #StemCells #Biotech #FDAApproval

Join us for an informative webinar: ?????????????? ?????????????????????? ???????? ??????????: ???????? ?????????????? ???? ?????????????????? ?????????????????????????????? ?????? ???????????????????? Industry experts Dr. Benjamin Fryer and Dr. Christina Jones, Ph.D. will share their scientific insights on efficient methods for differentiating iPSCs into cardiomyocytes and natural killer cells and tackling concerns over uncontrolled proliferation, genetic mutations, and other safety risks. ?? Date: Mar 20, 2025 ?? Time: 2:00-3:00 PM EDT Don't miss this opportunity to enhance your knowledge and stay ahead in the field of cell therapy development. Register now! ?? Register now: https://lnkd.in/gkdyja5U #CellTherapy #iPSCs #RegenerativeMedicine #Webinar #Pluristyx #CharlesRiver

Pretty darn cool technology towards a "universal stem cell" #stemcells #celltherapy #regenerativemedicine #iPSC

We are profoundly saddened by the loss of Dr. Roger Pedersen, a distinguished Stanford professor. For more than four decades, Roger’s pioneering work in early mammalian development and stem cell biology helped shape the foundation of regenerative medicine as we know it today. Roger's contributions to the scientific community have been immense. He was a brilliant scientist, a dedicated mentor, a passionate advocate for stem cell research, and a true pioneer in the field.? His curiosity, kindness, and tireless dedication to advancing science left an enduring impact on the research community and beyond. At Pluristyx, we were incredibly fortunate to benefit from Roger’s insights and expertise as a member of our Scientific Advisory Board. His was a life well lived with a lasting legacy that continues to shape the future of medicine – one that we can all hope to aspire to. ? Our deepest sympathies go out to his family, friends, and colleagues. He will be greatly missed.?

????????????????????????????? ?????????????????????????? ?????? ???? ?????????? ?????? ?????????? ???? ????????????????????? Today, we honor the incredible women at Pluristyx, Inc. who are making groundbreaking contributions to #CellTherapy and #RegenerativeMedicine. Their dedication, passion, and brilliance inspire us all. From pioneering research to transformative solutions, these women are shaping the future of science and technology. Let's continue to support and empower women (and girls) in STEM, ensuring a brighter, more inclusive future for all. #WomenInScience #STEM #InternationalDayOfWomenAndGirlsInScience #Pluristyx

?? ??.??. ???????????? ???????????????? ?????? ???????? ??????????????? ?????????????????????? We're excited to announce the issuance of U.S. Patent No. 12,178,835 for our exclusively licensed iACT Stealth? technology! This innovation helps cell therapy products avoid rejection, reducing or eliminating the need for immunosuppression. It is available as a stand-alone product or in combination with FailSafe? technology and our iPSCs. ?? Patents have also been issued in Australia, China, Israel, Japan, Korea, and Great Britain, with more pending globally. ?? Check out our press release: https://lnkd.in/g7meE9UW #CellTherapy #Innovation #Healthcare #Biotech #Pluristyx